Solstein Capital’s Organon & Co OGN Stock Holding History

Solstein Capital’s Portfolio OGN Stock Details OGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-60	Closed	-$2K	–	409
2021 Q4	$2K	Hold	60	–	–	﹤0.01%	399
2021 Q3	$2K	Sell	60 -9	-13%	-$288	﹤0.01%	439
2021 Q2	$2K	Buy	+69	New	+$2.27K	﹤0.01%	419

Other funds holding OGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $14.7B AUM 12.5% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Solstein Capital's OGN Position: Q1 2022 in Review

Solstein Capital sold out of Organon & Co (OGN) in Q1 2022, closing a stake of 60 shares — an estimated $2K sold.

Solstein Capital first reported a position in OGN in Q2 2021 and held it in 3 quarters. The position peaked at $2K in Q4 2021. 818 funds tracked by Wall St. Rank hold OGN as of Q1 2022.

Solstein Capital reported no remaining Organon & Co position as of Q1 2022 after selling out during the quarter.
Solstein Capital sold 60 Organon & Co shares in Q1 2022, an estimated $2K.
Solstein Capital first reported a position in Organon & Co in Q2 2021 and held it in 3 quarters.
Solstein Capital's Organon & Co position peaked at $2K in Q4 2021.
818 funds tracked by Wall St. Rank held Organon & Co as of Q1 2022.

Based on Solstein Capital's 13F filing for Q1 2022, filed 5 May 2022.